ASX Stocks Trading Below Their Revenue: Here Are 8, Why They’re Discounted and If They Can Re-Rate

There are a handful of ASX Stocks Trading Below Their Revenue – that is to say that their market capitalisation is barely above, or even below its revenue. At first glance, any such company may scream ‘buy’. To which we’d say not so fast.

When a company trades at or below its annual revenue, the market is making a statement about its margins, growth prospects, competitive position, or balance‑sheet risk. Sometimes the market is wrong by mispricing early‑stage companies or ignoring structural improvements. Sometimes the market is right, potentially signalling that the business model is fragile, cyclical, or structurally impaired.

The common thread is that the market is sceptical. But the reasons for that scepticism differ, and understanding those nuances is essential. The following companies illustrate the breadth of reasons behind low revenue multiples — and the potential pathways out of them.

8 ASX Stocks Trading Below Their Revenue

1. MyEco Group (ASX:MCO)

This company, once called Secos Group, was the inspiration for this article as it guided to $15.8m revenue for FY26 but its market cap is just $12m. You see, MyEco Group is a small, early‑stage sustainability business operating in a sector that investors often treat with caution. The company’s revenue base is modest, and its market cap sits slightly below its FY26 guidance. In one sense, the discount reflects execution risk: early‑stage companies must prove they can scale, maintain margins, and convert pipeline into contracted revenue.

The market is also signalling scepticism about the durability of demand. Sustainability products can be cyclical, sensitive to consumer sentiment, and exposed to competition from larger incumbents. MyEco’s challenge is to demonstrate repeatable revenue, margin stability, and a credible pathway to scale. If it can do so, the revenue multiple could expand quickly: small caps often re‑rate sharply once they prove operating leverage.

2. Pointerra (ASX:3DP)

Pointerra operates in 3D geospatial data processing — a niche but growing sector. The company’s revenue is lumpy because it depends heavily on government and infrastructure contracts. Markets dislike lumpiness. When revenue arrives in irregular bursts, investors struggle to model forward earnings, and the stock trades at a discount.

Pointerra’s technology is respected, but the company has historically struggled to convert technical capability into predictable commercial scale. The market cap roughly matches annual revenue, reflecting a belief that the business is valuable but not yet proven. If Pointerra can diversify its customer base, reduce contract lumpiness, and demonstrate recurring revenue, the multiple could expand. Until then, the market prices it cautiously. Its market cap is just above its $17-20m revenue guidance, but barely.

3. Knosys (ASX:KNO)

Knosys is capped at $5.4m but has guided to revenue more than double that. It is a knowledge‑management software company — a category that should, in theory, command higher multiples due to recurring revenue. Yet Knosys trades at the multiple it does. We think the reasons are obvious: growth has been slow, margins have been inconsistent, and profitability remains elusive.

The market is signalling that Knosys has not yet demonstrated the scalability expected of SaaS businesses. Investors want evidence of net revenue retention, customer expansion, and operating leverage. Without those, the stock trades like a low‑growth IT services business rather than a SaaS platform. The discount reflects scepticism, not dismissal. If Knosys can stabilise margins and show consistent ARR growth, the market cap could re‑rate quickly. But until then, the valuation remains compressed.

4. BSA (ASX:BSA)

BSA is one of the most extreme examples of revenue‑multiple compression on the ASX. With revenue around A$400m and a market cap of just A$22.59m, the company trades at roughly six cents for every dollar of revenue. This discount reflects the economics of contracting businesses. Margins are thin, competition is intense, and cash flow can be volatile. Contracting companies often face cost overruns, project delays, and customer disputes. And of course, the elephant in the room is the fact that it lost its contract with the NBN last year and it led to shares crashing over 75% in the day.

Investors therefore treat its revenue as low‑quality unless margins are stable and cash conversion is strong. And even then, investors seemingly have the attitude that it could be cut off at any time.  To re‑rate, the company would need to disprove that.

5. Service Stream (ASX:SSM)

Service Stream is a large contracting and infrastructure services business. It is capped at $1.5bn but its revenue base is even higher – at $2bn. This discount reflects the same dynamics seen in BSA, but with more stability: contracting businesses rarely command high revenue multiples because margins are thin and growth is tied to project cycles. And of course, it has not (at least not yet) had a moment as BSA did when it lost the NBN.

Service Stream has historically been well‑managed, but the sector itself is out of favour. Investors prefer businesses with recurring revenue, pricing power, and high margins. Contracting companies lack these characteristics, so they trade at low multiples even when well run.

The market is not signalling distress; it is simply applying a sector‑wide discount. For Service Stream to re‑rate, it would need to demonstrate margin expansion or move into higher‑value service lines.

6. Helloworld (ASX:HLO)

Helloworld trades slightly above its revenue (with a $240m market cap and $200m revenue), but still within the low‑multiple cohort. Travel agencies operate in a structurally challenged sector: margins are thin, competition is intense, and consumer behaviour is shifting toward direct booking platforms.

The market cap reflects cautious optimism. Helloworld has survived industry consolidation and demonstrated resilience, but investors remain wary of the sector’s long‑term economics and the fact that it is smaller than the majors such as Flight Centre. The revenue multiple suggests the market believes the business is stable but not high‑growth.

To expand its multiple, we believe Helloworld will need to demonstrate digital transformation, margin improvement, or new revenue streams. Until then, it trades at a modest premium to revenue.

7. Mayne Pharma (ASX:MYX)

Mayne Pharma is a generic pharmaceuticals company — a sector known for pricing pressure, regulatory risk, and intense competition. The company’s revenue base is large (at $500m), but the market cap sits well below it – barely half, in fact. This discount reflects several factors: historical strategic missteps, margin compression, and the inherent volatility of generics.

By generics we mean re-made versions of drugs. New drugs get periods of exclusivity but after a while, other companies can put biosimilars out to the market and this inevitably leads to a ‘race to the bottom on pricing’. Not quite to the bottom but neither does the pricing stay at monopoly levels. Investors treat generic pharmaceutical revenue as low‑quality because pricing collapses quickly when competitors enter. Mayne’s valuation suggests the market believes the business is structurally challenged but potentially recoverable.

If Mayne can stabilise margins, reduce debt, and demonstrate consistent cash flow, the revenue multiple could expand. But the market will require sustained evidence, not short‑term improvements.

8. Australian Clinical Labs (ASX:ACL)

ACL operates in pathology — a sector that boomed during COVID‑19 and then sharply derated. The company’s revenue remains substantial (at $650m), but the market cap sits below annual revenue at $416m. This discount reflects the post‑pandemic normalisation of testing volumes and investor scepticism about long‑term growth.

Pathology businesses have stable revenue, but growth is modest and margins can be pressured by regulatory changes. ACL’s valuation suggests the market believes the business is solid but not high‑growth.

To re‑rate, ACL would need to demonstrate margin resilience, operational efficiency, or new service lines. The revenue multiple reflects caution, not pessimism.

The bottom line

A low revenue multiple is not inherently negative. It can signal opportunity if the market is mispricing risk or ignoring structural improvements. But it can also signal genuine structural issues within the business itself or the sector. The challenge for investors is working out why.